CX-01 Heparin Derivative Investigated for Older Patients With AML

A randomized phase II trial investigated whether adding  CX-01, a low anticoagulant heparin derivative, to standard care improves outcomes in older patients with acute myeloid leukemia.

Source: CancerNetwork - June 14, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news